TheTRHRGene Is Associated with Hypothalamo-Pituitary Sensitivity to Levothyroxine

Abstract

Background: Thyroidectomized patients need variable doses of levothyroxine (LT₄) to obtain target thyroid-stimulating hormone (TSH) levels. Individual feedback set-points have been hypothesized and the influence of several genes in the regulation of the pituitary-thyroid axis has been demonstrated. Objectives: We hypothesized that genetic variants of the TRHR gene could be associated with a different hypothalamo-pituitary sensitivity to thyroid hormone feedback. Methods: We retrospectively analyzed 84 thyroidectomized patients with no residual thyroid function and undetectable thyroglobulin levels. Patients were evaluated under LT₄ resulting in TSH levels detectable but <0.5 μIU/ml. The two SNPs rs3134105 and rs3110040 were identified as informative markers of the TRHR gene. Genotyping was performed using high-resolution melting technology. Genotype distribution was compared between the patients and 99 euthyroid controls. Results: The selected SNPs were in linkage disequilibrium and only rs3134105 was further considered. A significant difference between the three possible genotypes for rs3134105 was found for TSH (p = 0.04) and free thyroxine (fT₄)/TSH ratio (p = 0.02). Moreover, despite similar serum concentrations of free triiodothyronine (fT₃) and fT₄, carriers of at least one A allele of rs3134105 had significantly lower serum TSH levels (p = 0.01) as well as higher fT₃/TSH (p = 0.01) and fT₄/TSH ratios (p < 0.01). Conclusions: We demonstrated an association between serum TSH levels and discrete alleles of the TRHR gene in totally thyroidectomized patients under LT₄ therapy. Therefore, the TRHR gene seems to be a determinant of hypothalamo-pituitary sensitivity to LT₄.

The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation

“…Research has shown associations between LT4 needs and LBM measured by Dual Energy X-ray Absorptiometry, as well as genetic factors and TSH serum levels in patients undergoing LT4 therapy. (20, 21, 24) Absence of these predictors in our model development leaves space for future algorithm improvement. However, these predictors require more invasive or expensive testing and our goal was to develop a method with readily obtainable data.…”

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

“…In both trials, patients were then enrolled into open extension phases [24, 25]. In the DECISION trial, patients who had progressed on sorafenib were permitted to continue to receive sorafenib until further disease progression and approximately a quarter (26.6%) of patients did so [53, 54]. In both the SELECT and DECISION trials, patients in the placebo arms could cross over from the placebo arm to the active treatment arm.…”

The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic–pituitary–thyroid axis

“…41 For instance, in athyreotic patients treated with LT4, the sensitivity of TSH to feedback by FT4 has been shown to vary genetically. 42 If the thyroid function and FT4 production rate decline, as is the case in a patient with subclinical hypothyroidism, TSH-feedforward on FT3 was found to be required for FT3 protection. The latter involves two distinct mechanisms because TSH regulates more than one enzymatic reaction, namely, the intra-thyroidal conversion of FT4-FT3 and secretion of FT3.…”